We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Analysis of Lesions Provides Accurate Esophageal Cancer Test

By LabMedica International staff writers
Posted on 31 Aug 2016
Barrett's Esophagus is a common condition that affects an estimated 1.5 million people in the UK alone, although many are undiagnosed. More...
This condition involves normal cells in the esophagus being replaced by an unusual cell type called Barrett's Esophagus, and is thought to be a consequence of chronic reflux or heartburn.

People with Barrett's have an increased risk of developing esophageal cancer, a neoplasm that has a five year survival of 15% and although the overall lifetime risk of developing esophageal cancer in people with Barrett's is significant, most Barrett's patients will not develop cancer in their lifetime. It is the unfortunate few who will develop an aggressive cancer.

An international team of scientists led by those at the Queen Mary University of London (UK) followed up more than 300 Barrett's patients over three years, and analyzed around 50,000 cells in the process. They performed genetic analysis of individual cells and measured the genetic diversity in each lesion to track it over time. The results validated a previous group's discovery that measurement of the genetic diversity between Barrett's cells in any given lesion is a good predictor of which patients are at high risk of developing cancer. Genetic diversity describes how diverse the genetic make-up of individual cells is in any given group of cells.

In addition, the team found that there were no significant changes in genetic diversity during the three years that the patients were followed. Clonal expansions are rare, being detected once every 36.8 patient years, and growing at an average rate of 1.58 cm2 per year, often involving the p16 locus. This suggests that the genetic diversity amongst a person's Barrett's cells is essentially fixed over time, and mutations have little impact on the lesion's development. Whenever someone's Barrett's is tested, their future risk can be predicted regardless of how soon it is after the appearance of abnormal cells.

Trevor A. Graham PhD, a lecturer in Tumor Biology and senior author of the study said, “Our findings are important because they imply that a person's risk of developing esophageal cancer is fixed over time. In other words, we can predict from the outset which Barrett's patients fall into a high risk group of developing cancer and that risk does not change thereafter.” The study was published on August 19, 2016, in the journal Nature Communications.

Related Links:
Queen Mary University of London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.